Meibomian gland dysfunction is highly prevalent among first-time visitors at a Norwegian dry eye specialist clinic
- PMID: 34862425
- PMCID: PMC8642422
- DOI: 10.1038/s41598-021-02738-6
Meibomian gland dysfunction is highly prevalent among first-time visitors at a Norwegian dry eye specialist clinic
Abstract
To investigate the prevalence of meibomian gland dysfunction (MGD) in patients presenting with subjective dry eye-related symptoms at their first-time consultation in a Norwegian specialized ocular surface clinic. Additionally, to explore the accuracy of the ocular surface disease index score (OSDI) as an extensively applied tool to assess the severity of dry eye symptoms and MGD diagnosis. Patients with subjective dry eye-related complaints (n = 900) attending the clinic for the first time, from 2012 to 2016, were included in the study. At the baseline, patients completed the OSDI questionnaire. Subsequently, objective clinical tests, including fluorescein break-up time (FBUT), Schirmer-I test, ocular surface staining (OSS), and meibomian gland function assessment using gland expressibility and meibum quality were performed. The association between MGD and its severity in relation to symptom severity defined by OSDI-score was examined. MGD was found in 93.8% of the study group. MGD prevalence was not significantly different between groups based on age (p = 0.302) or sex (p = 0.079). There was a significant association between severity of MGD and dry eye-related symptoms (p = 0.014). OSS was significantly higher in patients with severe symptoms (p = 0.031). Sensitivity and specificity of positive symptom-score (OSDI ≥ 13) for disclosing MGD were 85.5% and 30.4%, respectively. MGD was highly prevalent, not associated with age and sex. OSDI ≥ 13 had high sensitivity and high positive predictive value (PPV), but low specificity and negative predictive value (NPV) for disclosing MGD. This underscores the importance of meibomian gland assessment in patients with dry eye-related symptoms.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Functional and Morphological Evaluation of Meibomian Glands in the Assessment of Meibomian Gland Dysfunction Subtype and Severity.Am J Ophthalmol. 2020 Jan;209:160-167. doi: 10.1016/j.ajo.2019.09.005. Epub 2019 Sep 14. Am J Ophthalmol. 2020. PMID: 31526799
-
Efficacy and safety of intense pulsed light of upper and lower eyelids in Meibomian gland dysfunction: A prospective multicentric study.Eur J Ophthalmol. 2024 May;34(3):700-707. doi: 10.1177/11206721231199121. Epub 2023 Sep 6. Eur J Ophthalmol. 2024. PMID: 37671407
-
Tear Production Levels and Dry Eye Disease Severity in a Large Norwegian Cohort.Curr Eye Res. 2018 Dec;43(12):1465-1470. doi: 10.1080/02713683.2018.1514055. Epub 2018 Sep 5. Curr Eye Res. 2018. PMID: 30183390
-
Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction.Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559. doi: 10.1002/14651858.CD013559. Cochrane Database Syst Rev. 2020. PMID: 32182637 Free PMC article.
-
A review of rabbit models of meibomian gland dysfunction and scope for translational research.Indian J Ophthalmol. 2023 Apr;71(4):1227-1236. doi: 10.4103/IJO.IJO_2815_22. Indian J Ophthalmol. 2023. PMID: 37026253 Free PMC article. Review.
Cited by
-
Age Associations with Dry Eye Clinical Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study.Ophthalmol Sci. 2023 Jan 12;3(2):100270. doi: 10.1016/j.xops.2023.100270. eCollection 2023 Jun. Ophthalmol Sci. 2023. PMID: 36846104 Free PMC article.
-
Prevalence, Severity, and Treatment Outcomes of Meibomian Gland Dysfunction in Patients With Dry Eye Symptoms at a Tertiary Care Center in South India.Cureus. 2022 Jun 7;14(6):e25703. doi: 10.7759/cureus.25703. eCollection 2022 Jun. Cureus. 2022. PMID: 35812580 Free PMC article.
-
Spanish Cross-Cultural Adaptation, Rasch Analysis and Validation of the Ocular Comfort Index (OCI) Questionnaire.Int J Environ Res Public Health. 2022 Nov 17;19(22):15142. doi: 10.3390/ijerph192215142. Int J Environ Res Public Health. 2022. PMID: 36429862 Free PMC article.
-
Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics.Ophthalmol Ther. 2025 Feb;14(2):283-293. doi: 10.1007/s40123-024-01076-w. Epub 2025 Jan 7. Ophthalmol Ther. 2025. PMID: 39775405 Free PMC article. Review.
-
Phospholipid Nanoemulsion-Based Ocular Lubricant for the Treatment of Dry Eye Subtypes: A Multicenter and Prospective Study.Ophthalmol Ther. 2024 Dec;13(12):3203-3213. doi: 10.1007/s40123-024-01058-y. Epub 2024 Nov 1. Ophthalmol Ther. 2024. PMID: 39485593 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical